PD-1抗体-话题@MedSci

#PD-1抗体#

44篇内容 | 2373人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1577096, encodeId=a22715e709693, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Nat Biothechnol：装上了迷你版PD-1抗体的CAR-T细胞，对抗实体瘤如鱼得水, objectType=article, longId=146695, objectId=ffc91466958d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffc91466958d, replyNumber=0, likeNumber=71, createdTime=2018-08-17, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffc91466958d, moduleTitle=Nat Biothechnol：装上了迷你版PD-1抗体的CAR-T细胞，对抗实体瘤如鱼得水, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffc91466958d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577095, encodeId=28d215e709598, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=百济神州启动PD-1抗体联合化疗治疗非小细胞肺癌的临床3期试验, objectType=article, longId=146648, objectId=02c614664864, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=02c614664864, replyNumber=0, likeNumber=64, createdTime=2018-08-16, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=02c614664864, moduleTitle=百济神州启动PD-1抗体联合化疗治疗非小细胞肺癌的临床3期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=02c614664864)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577094, encodeId=928715e70947c, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Cancer Discover：中国工程院院士王学浩团队首次发现YAP抑制剂联合PD-1抗体或肿瘤疫苗可显著增强免疫治疗效果, objectType=article, longId=145862, objectId=254214586298, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=254214586298, replyNumber=0, likeNumber=77, createdTime=2018-08-06, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=254214586298, moduleTitle=Cancer Discover：中国工程院院士王学浩团队首次发现YAP抑制剂联合PD-1抗体或肿瘤疫苗可显著增强免疫治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=254214586298)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577093, encodeId=c8c515e709368, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=百济神州公布其PD-1抗体Tislelizumab治疗霍奇金淋巴瘤中的关键性临床试验初步结果, objectType=article, longId=145093, objectId=17a914509309, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17a914509309, replyNumber=0, likeNumber=90, createdTime=2018-07-26, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17a914509309, moduleTitle=百济神州公布其PD-1抗体Tislelizumab治疗霍奇金淋巴瘤中的关键性临床试验初步结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17a914509309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577092, encodeId=ff2715e709268, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=JCI：Dinaciclib诱导免疫原性细胞死亡并增强PD-1抗体介导的肿瘤抑制, objectType=article, longId=130728, objectId=7b92130e289e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b92130e289e, replyNumber=0, likeNumber=68, createdTime=2018-02-28, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b92130e289e, moduleTitle=JCI：Dinaciclib诱导免疫原性细胞死亡并增强PD-1抗体介导的肿瘤抑制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b92130e289e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577091, encodeId=699915e709135, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=全球针对肝癌的PD-1抗体获FDA批准，奋起直追，国产PD-1抗体顺利进入三期临床, objectType=article, longId=125937, objectId=16d012593e87, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=16d012593e87, replyNumber=0, likeNumber=83, createdTime=2018-01-10, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=16d012593e87, moduleTitle=全球针对肝癌的PD-1抗体获FDA批准，奋起直追，国产PD-1抗体顺利进入三期临床, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=16d012593e87)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577090, encodeId=5abd15e709089, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=EUR J Cancer：使用PD-1抗体 pembrolizumab治疗转移性黑色素瘤及非黑素瘤皮肤癌中的着色性干皮症, objectType=article, longId=124993, objectId=4f6412499324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f6412499324, replyNumber=0, likeNumber=37, createdTime=2017-12-30, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f6412499324, moduleTitle=EUR J Cancer：使用PD-1抗体 pembrolizumab治疗转移性黑色素瘤及非黑素瘤皮肤癌中的着色性干皮症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f6412499324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577089, encodeId=df8f15e708911, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=JCI：IFN-γ相关mRNA数据能够预测患者对PD-1抗体的响应, objectType=article, longId=124176, objectId=15f61241e6ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=15f61241e6ef, replyNumber=0, likeNumber=62, createdTime=2017-12-23, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=15f61241e6ef, moduleTitle=JCI：IFN-γ相关mRNA数据能够预测患者对PD-1抗体的响应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=15f61241e6ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577088, encodeId=54db15e7088b0, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=EUR J CANCER：转移性皮肤顶浆分泌腺癌对PD-1抗体pembrolizumab的响应, objectType=article, longId=124076, objectId=5d1f1240e680, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d1f1240e680, replyNumber=0, likeNumber=77, createdTime=2017-12-22, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d1f1240e680, moduleTitle=EUR J CANCER：转移性皮肤顶浆分泌腺癌对PD-1抗体pembrolizumab的响应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d1f1240e680)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577087, encodeId=864515e708741, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Cancer cell：那些促进肿瘤生长，还吃PD-1抗体的巨噬细胞，科学家终于找到消灭你的好办法了, objectType=article, longId=122346, objectId=f065122346e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f065122346e3, replyNumber=0, likeNumber=64, createdTime=2017-12-06, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f065122346e3, moduleTitle=Cancer cell：那些促进肿瘤生长，还吃PD-1抗体的巨噬细胞，科学家终于找到消灭你的好办法了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f065122346e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577086, encodeId=bf5515e708698, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=重要警示！2篇论文证实：这种PD-1抗体联合疗法，效果不佳还“有害”, objectType=article, longId=112124, objectId=d7d011212479, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d7d011212479, replyNumber=0, likeNumber=61, createdTime=2017-09-08, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d7d011212479, moduleTitle=重要警示！2篇论文证实：这种PD-1抗体联合疗法，效果不佳还“有害”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d7d011212479)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577085, encodeId=7fdb15e708531, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=药明生物和誉衡药业将PD-1抗体GLS-010授权给Arcus Biosciences, objectType=article, longId=110512, objectId=f46311051235, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f46311051235, replyNumber=0, likeNumber=90, createdTime=2017-08-24, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f46311051235, moduleTitle=药明生物和誉衡药业将PD-1抗体GLS-010授权给Arcus Biosciences, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f46311051235)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577084, encodeId=500f15e708455, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Cell:免疫疗法大牛James Allison全新：PD-1抗体与CTLA-4抗体原来如此不同, objectType=article, longId=108739, objectId=d029108e3926, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d029108e3926, replyNumber=0, likeNumber=57, createdTime=2017-08-16, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d029108e3926, moduleTitle=Cell:免疫疗法大牛James Allison全新：PD-1抗体与CTLA-4抗体原来如此不同, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d029108e3926)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577083, encodeId=379f15e708343, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=JAMA DERMAT：不可思议！PD-1抗体让癌症患者“白发”变“黑发”, objectType=article, longId=105608, objectId=67df105608ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67df105608ba, replyNumber=0, likeNumber=67, createdTime=2017-07-16, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67df105608ba, moduleTitle=JAMA DERMAT：不可思议！PD-1抗体让癌症患者“白发”变“黑发”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=67df105608ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577082, encodeId=7a4e15e7082ff, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=SCI TRANSL MED：难怪免疫治疗对有些患者无效！原来PD-1抗体都被巨噬细胞吃了, objectType=article, longId=98794, objectId=935098e94a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=935098e94a3, replyNumber=0, likeNumber=80, createdTime=2017-05-17, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=935098e94a3, moduleTitle=SCI TRANSL MED：难怪免疫治疗对有些患者无效！原来PD-1抗体都被巨噬细胞吃了, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=935098e94a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577081, encodeId=abd715e70818c, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Blood：PD-1抗体pembrolizumab治疗慢性淋巴细胞白血病Richter’s转化有效, objectType=article, longId=96976, objectId=a9ad969e617, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a9ad969e617, replyNumber=0, likeNumber=64, createdTime=2017-04-26, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a9ad969e617, moduleTitle=Blood：PD-1抗体pembrolizumab治疗慢性淋巴细胞白血病Richter’s转化有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a9ad969e617)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577080, encodeId=984f15e708078, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Nature：PD-1抗体为何对有些患者无效？肿瘤大小在“作祟”！, objectType=article, longId=95723, objectId=961395e23e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=961395e23e4, replyNumber=0, likeNumber=76, createdTime=2017-04-15, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=961395e23e4, moduleTitle=Nature：PD-1抗体为何对有些患者无效？肿瘤大小在“作祟”！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=961395e23e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577079, encodeId=cd7715e7079c1, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=启动临床试验！神药（二甲双胍）+神药（PD-1抗体）？, objectType=article, longId=89474, objectId=9173894e49d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9173894e49d, replyNumber=0, likeNumber=77, createdTime=2017-02-22, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9173894e49d, moduleTitle=启动临床试验！神药（二甲双胍）+神药（PD-1抗体）？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9173894e49d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577078, encodeId=c1c415e70787e, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Nat Commun：高福院士揭示PD-1抗体作用的结构学机制, objectType=article, longId=88591, objectId=770688591e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=770688591e1, replyNumber=0, likeNumber=81, createdTime=2017-02-12, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=770688591e1, moduleTitle=Nat Commun：高福院士揭示PD-1抗体作用的结构学机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=770688591e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1577077, encodeId=5ae115e707704, content=<a href='/topic/show?id=a2a613914cd' target=_blank style='color:#2F92EE;'>#PD-1抗体#</a>, objectTitle=Sci Transl Med：局部化疗携手PD-1抗体治疗，打击肿瘤火力翻倍！, objectType=article, longId=86139, objectId=9047861398f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9047861398f, replyNumber=0, likeNumber=57, createdTime=2017-01-01, rootId=0, userName=1249857fm37暂无昵称, userId=021d16387966, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9047861398f, moduleTitle=Sci Transl Med：局部化疗携手PD-1抗体治疗，打击肿瘤火力翻倍！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9047861398f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1抗体

2020-05-29

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

Nat Biothechnol：装上了迷你版PD-1抗体的CAR-T细胞，对抗实体瘤如鱼得水

2018-08-17

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

百济神州启动PD-1抗体联合化疗治疗非小细胞肺癌的临床3期试验

2018-08-16

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

Cancer Discover：中国工程院院士王学浩团队首次发现YAP抑制剂联合PD-1抗体或肿瘤疫苗可显著增强免疫治疗效果

2018-08-06

hb2008ye (审核中...)

前往app查看评论内容

#PD-1抗体#

百济神州公布其PD-1抗体Tislelizumab治疗霍奇金淋巴瘤中的关键性临床试验初步结果

2018-07-26

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

JCI：Dinaciclib诱导免疫原性细胞死亡并增强PD-1抗体介导的肿瘤抑制

2018-02-28

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

全球针对肝癌的PD-1抗体获FDA批准，奋起直追，国产PD-1抗体顺利进入三期临床

2018-01-10

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

EUR J Cancer：使用PD-1抗体 pembrolizumab治疗转移性黑色素瘤及非黑素瘤皮肤癌中的着色性干皮症

2017-12-30

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

JCI：IFN-γ相关mRNA数据能够预测患者对PD-1抗体的响应

2017-12-23

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

EUR J CANCER：转移性皮肤顶浆分泌腺癌对PD-1抗体pembrolizumab的响应

2017-12-22

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

Cancer cell：那些促进肿瘤生长，还吃PD-1抗体的巨噬细胞，科学家终于找到消灭你的好办法了

2017-12-06

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

重要警示！2篇论文证实：这种PD-1抗体联合疗法，效果不佳还“有害”

2017-09-08

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

药明生物和誉衡药业将PD-1抗体GLS-010授权给Arcus Biosciences

2017-08-24

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

Cell:免疫疗法大牛James Allison全新：PD-1抗体与CTLA-4抗体原来如此不同

2017-08-16

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

JAMA DERMAT：不可思议！PD-1抗体让癌症患者“白发”变“黑发”

2017-07-16

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

SCI TRANSL MED：难怪免疫治疗对有些患者无效！原来PD-1抗体都被巨噬细胞吃了

2017-05-17

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

Blood：PD-1抗体pembrolizumab治疗慢性淋巴细胞白血病Richter’s转化有效

2017-04-26

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

Nature：PD-1抗体为何对有些患者无效？肿瘤大小在“作祟”！

2017-04-15

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

启动临床试验！神药（二甲双胍）+神药（PD-1抗体）？

2017-02-22

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

Nat Commun：高福院士揭示PD-1抗体作用的结构学机制

2017-02-12

1249857fm37暂无昵称 (审核中...)

前往app查看评论内容

#PD-1抗体#

Sci Transl Med：局部化疗携手PD-1抗体治疗，打击肿瘤火力翻倍！

2017-01-01

科室
- - 订阅+
  - 更多科室
工具
服务